Evolent Health, Inc (EVH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evolent Health, Inc (EVH) trades at $5.92 with AI Score 19/100 (Grade F). Evolent Health, Inc. provides clinical and administrative solutions to payers and providers in the United States. Market cap: $666.45M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026EVH stock analysis for 2026: Analysts have set a consensus price target of $6.50 for Evolent Health, Inc, suggesting 9.7% upside from the current price of $5.92. The AI MoonshotScore is 19/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
EVH: 1/1 perspectives are bearish.
How is this calculated? →Evolent Health, Inc (EVH) Healthcare & Pipeline Overview
Evolent Health, Inc. delivers clinical and administrative solutions for payers and providers, focusing on value-based care. The company's integrated platform, Identifi, and specialty care management services in oncology and cardiology, position it within the evolving healthcare landscape, emphasizing cost-effective patient-centric care.
What Is the Investment Thesis for EVH?
Evolent Health operates in the growing healthcare information services market, driven by the shift towards value-based care. The company's Identifi platform and clinical solutions offer potential for revenue growth by improving care coordination and cost management. With a market capitalization of $666.45M, Evolent Health's future performance will depend on its ability to scale its services and manage its negative profit margin of -26.3%. Key catalysts include expanding its client base and further penetration into the oncology and cardiology markets. Potential risks include competition and the ability to maintain technological advantage.
Based on FMP financials and quantitative analysis
EVH Key Highlights
- Market Cap of $666.45M reflects its current valuation in the healthcare information services market.
- Negative Profit Margin of -26.3% indicates challenges in achieving profitability, requiring focus on cost management and revenue growth.
- Gross Margin of 12.9% suggests potential for improvement through operational efficiencies and pricing strategies.
- Beta of 0.37 indicates lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- No Dividend Yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.
Who Are EVH's Competitors?
EVH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| UNH UnitedHealth Group Incorporated | $416.25 | -2.14% | $378.02B | 76 |
| HUM Humana Inc. | $392.86 | -0.98% | $47.17B | 79 |
| CVS CVS Health Corporation | $102.14 | -2.47% | $130.32B | 74 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVH's Key Strengths?
- Integrated administrative and clinical platform.
- Proprietary Identifi technology.
- Expertise in value-based care models.
- Strong relationships with payers and providers.
What Are EVH's Weaknesses?
- Negative profit margin.
- Reliance on U.S. healthcare system.
- Limited geographic diversification.
- Competitive market.
What Could Drive EVH Stock Higher?
- Expansion of the Identifi platform to integrate new data analytics and care coordination features.
- Potential new partnerships with large healthcare providers in Q3 2026.
- Increasing adoption of value-based care models driving demand for Evolent Health's services.
- Launch of new specialty care management programs in Q4 2026.
What Are the Key Risks for EVH?
- Financial-distress signal — its Altman Z-Score of -0.42 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-77.9%) — the business is not currently generating profit on shareholder capital.
- Intense competition from larger, more established healthcare companies.
- Changes in healthcare regulations and policies could impact Evolent Health's business model.
- Economic downturn affecting healthcare spending and payer budgets.
- Technological advancements by competitors could erode Evolent Health's competitive advantage.
What Are the Growth Opportunities for EVH?
- Expansion of Identifi Platform: Evolent Health can expand the capabilities and market reach of its Identifi platform. The global healthcare analytics market is projected to reach $67.9 billion by 2029, growing at a CAGR of 24.7% from 2022. By enhancing Identifi's data analytics and care coordination features, Evolent Health can attract more payers and providers seeking to improve population health management and reduce costs. This expansion can be achieved through strategic partnerships and investments in technology development.
- Penetration of Oncology and Cardiology Markets: Evolent Health's Clinical Solutions segment has significant growth potential in the oncology and cardiology markets. The global oncology market is expected to reach $286.6 billion by 2031, growing at a CAGR of 12.4% from 2021. Similarly, the cardiology market is projected to reach $39.5 billion by 2028. By offering specialized care management services tailored to these high-cost areas, Evolent Health can capture a larger share of the market and improve patient outcomes.
- Strategic Partnerships with Payers and Providers: Forming strategic partnerships with payers and providers can drive growth for Evolent Health. By collaborating with healthcare organizations, Evolent Health can integrate its solutions into their existing workflows and gain access to a broader patient population. These partnerships can also lead to the development of new services and solutions that address specific needs within the healthcare industry. The timeline for establishing these partnerships can vary, but typically takes 6-12 months to finalize.
- Adoption of Value-Based Care Models: The increasing adoption of value-based care models presents a significant growth opportunity for Evolent Health. As healthcare organizations shift away from fee-for-service models, they require solutions that can help them manage risk, improve care coordination, and reduce costs. Evolent Health's integrated administrative and clinical platform is well-positioned to support this transition. The adoption of value-based care is expected to continue growing, driven by government initiatives and the need to improve healthcare affordability.
- Geographic Expansion: Evolent Health can expand its geographic reach by targeting new markets and regions. The company currently operates in the United States, but there is potential to expand internationally. By entering new markets, Evolent Health can diversify its revenue streams and reduce its reliance on the U.S. healthcare system. The timeline for geographic expansion can vary depending on the market, but typically takes 1-2 years to establish a presence and build relationships with local payers and providers.
What Opportunities Does EVH Have?
- Expansion of Identifi platform capabilities.
- Penetration of oncology and cardiology markets.
- Strategic partnerships with healthcare organizations.
- Adoption of value-based care models.
What Threats Does EVH Face?
- Intense competition from larger healthcare companies.
- Changes in healthcare regulations and policies.
- Technological advancements by competitors.
- Economic downturn affecting healthcare spending.
What Are EVH's Competitive Advantages?
- Proprietary Technology: The Identifi platform provides a unique data aggregation and care management solution.
- Integrated Services: Offers a comprehensive suite of administrative and clinical services.
- Specialty Care Expertise: Focuses on high-cost areas like oncology and cardiology.
- Established Relationships: Strong partnerships with payers and providers.
What Does EVH Do?
Founded in 2011 and headquartered in Arlington, Virginia, Evolent Health, Inc. operates as a healthcare company that provides clinical and administrative solutions to payers and providers through its subsidiary, Evolent Health LLC. The company is structured into two primary segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services segment offers an integrated administrative and clinical platform designed for health plan administration and population health management. This includes financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management. A key component of this segment is Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, aiming to improve population health performance and deliver patient-centric, cost-effective care. The Clinical Solutions segment provides specialty care management services, supporting stakeholders in oncology and cardiology as they transition from fee-for-service to value-based care models. These services are designed to improve the total cost of care, regardless of the stakeholder's maturity stage or specific market dynamics.
What Products and Services Does EVH Offer?
- Provides clinical and administrative solutions to healthcare payers and providers.
- Offers an integrated platform for health plan administration and population health management.
- Delivers financial and administrative management services, including risk management and analytics.
- Utilizes Identifi, a proprietary technology system for data aggregation and care workflow management.
- Offers specialty care management services in oncology and cardiology.
- Supports the transition from fee-for-service to value-based care models.
- Focuses on improving patient outcomes and reducing the total cost of care.
How Does EVH Make Money?
- Generates revenue through contracts with payers and providers for its administrative and clinical solutions.
- Offers subscription-based access to its Identifi platform.
- Provides fee-based services for specialty care management in oncology and cardiology.
- Revenue is derived from health plan services, risk management, analytics, and reporting.
What Industry Does EVH Operate In?
Evolent Health operates within the healthcare information services industry, which is experiencing growth driven by the increasing adoption of value-based care models. The industry is characterized by a shift towards data-driven healthcare solutions and the need for improved care coordination. Evolent Health competes with other healthcare IT companies and consulting firms that offer similar services. The market is competitive, with companies vying to provide comprehensive solutions that address the challenges of managing population health and controlling healthcare costs. The industry is expected to continue growing as healthcare providers and payers seek to improve efficiency and outcomes.
Who Are EVH's Key Customers?
- Healthcare payers, including health plans and insurance companies.
- Healthcare providers, such as hospitals, physician groups, and integrated delivery networks.
- Specialty care delivery stakeholders in oncology and cardiology.
FY2026 estForward Outlook
Wall Street analysts project Evolent Health, Inc revenue of about $2.50B for fiscal 2026, with EPS near $0.18. The estimate reflects 11 contributing analysts.
ROE -78%Key Financial Metrics
Return on equity for Evolent Health, Inc stands at -77.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -81.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Evolent Health, Inc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.42 places it in the distress zone, a signal of elevated financial risk.
EVH Valuation & Market Position
With a $666.45M market cap, Evolent Health, Inc sits in the small-cap segment of the market. Relative to its peer group, EVH's quantitative score of 19/100 is below the peer average of 73/100.
EVH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Evolent Health's growth trajectory, indicating that leadership believes in the company's future.
- Community sentiment has turned increasingly positive, with discussions highlighting the company's innovative health solutions gaining traction.
- Market perception is shifting as Evolent's partnerships with healthcare providers are seen as a strong competitive advantage in the evolving health tech landscape.
- Analysts have noted a growing demand for value-based care solutions, positioning Evolent Health favorably as it aligns with industry trends.
Bear Case
- Despite positive sentiment, some analysts express concerns over Evolent's ability to scale operations efficiently amidst rapid growth.
- Community discussions reveal skepticism regarding the company's past performance and whether it can sustain its current momentum.
- Recent regulatory changes in the healthcare sector have raised uncertainties, leading some investors to adopt a cautious stance on Evolent's future prospects.
- There are lingering concerns about competition from larger players entering the health tech space, potentially overshadowing Evolent's market position.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
EVH Latest News
-
Q1 Earnings Outperformers: Evolent Health (NYSE:EVH) And The Rest Of The Healthcare Technology for Providers Stocks
StockStory · Jun 12, 2026
-
Q1 Earnings Outperformers: Evolent Health (NYSE:EVH) And The Rest Of The Healthcare Technology for Providers Stocks
Yahoo! Finance: EVH News · Jun 12, 2026
-
Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7
benzinga · Jun 12, 2026
-
Truist Raises Price Target on Evolent Health to $7 From $6, Keeps Buy Rating
MT Newswires · Jun 12, 2026
EVH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVH.
Price Targets
Consensus target: $6.50
EVH MoonshotScore
What does this score mean?
The MoonshotScore rates EVH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Q1 Earnings Outperformers: Evolent Health (NYSE:EVH) And The Rest Of The Healthcare Technology for Providers Stocks
Q1 Earnings Outperformers: Evolent Health (NYSE:EVH) And The Rest Of The Healthcare Technology for Providers Stocks
Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7
Truist Raises Price Target on Evolent Health to $7 From $6, Keeps Buy Rating
Leadership: Seth Barrie Blackley
CEO
Seth Barrie Blackley serves as the CEO of Evolent Health, Inc. His career reflects extensive experience in healthcare management and technology. Before Evolent Health, Blackley held leadership positions at The Advisory Board Company, focusing on healthcare strategy and consulting. He has a strong background in driving innovation and growth within the healthcare sector. Blackley's expertise lies in developing and implementing solutions that improve patient outcomes and reduce costs.
Track Record: Under Seth Blackley's leadership, Evolent Health has focused on expanding its integrated administrative and clinical platform, Identifi, and strengthening its presence in the oncology and cardiology markets. He has overseen the company's efforts to support the transition to value-based care models and improve care coordination. Key milestones include strategic partnerships with payers and providers, and enhancements to Evolent Health's technology offerings.
What Investors Ask About Evolent Health, Inc (EVH) — Healthcare
What does Evolent Health, Inc. do?
Evolent Health, Inc. operates as a healthcare company providing clinical and administrative solutions to payers and providers in the United States. The company's core offering is an integrated platform that supports health plan administration and population health management. Through its Identifi technology, Evolent Health aggregates and analyzes data, manages care workflows, and engages patients to deliver patient-centric, cost-effective care. Additionally, the company offers specialty care management services in areas like oncology and cardiology, aiding stakeholders in transitioning to value-based care models, thereby improving the total cost of care.
What do analysts say about EVH stock?
Analyst consensus on Evolent Health (EVH) stock reflects a mixed outlook, considering its position in the healthcare information services market. Key valuation metrics indicate a focus on growth potential, balanced against current profitability challenges. Analysts are closely watching Evolent Health's ability to scale its services, manage costs, and capitalize on the increasing adoption of value-based care models. The company's strategic initiatives in oncology and cardiology are also key areas of interest. Analyst ratings and price targets vary, reflecting differing perspectives on the company's execution and market opportunities.
What are the main risks for EVH?
Evolent Health faces several key risks. Intense competition in the healthcare information services market from larger, more established players could limit its growth potential. Changes in healthcare regulations and policies, such as those related to value-based care, could impact its business model and revenue streams. An economic downturn could reduce healthcare spending, affecting payer and provider budgets. Additionally, rapid technological advancements by competitors could erode Evolent Health's competitive advantage. The company's negative profit margin also poses a risk, requiring effective cost management and revenue growth strategies.
What are the key factors to evaluate for EVH?
Evolent Health, Inc (EVH) holds an AI score of 19/100 (low). Analysts target $6.50 (+10%). Not financial advice.
How frequently does EVH data refresh on this page?
EVH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EVH's recent stock price performance?
Evolent Health, Inc (EVH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated administrative and clinical platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EVH overvalued or undervalued right now?
Valuing Evolent Health, Inc (EVH) requires multiple metrics. Analysts target $6.50 (+10%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EVH?
Before investing in Evolent Health, Inc (EVH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Industry analysis is based on current market trends and reports.
- CEO profile is based on publicly available information.